R

Regulus Therapeutics

RGLS

1.69000
USD
-0.09
(-5.06%)
مفتوح الان
حجم التداول
3,032
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
95,580,179
أصول ذات صلة
A
ALNY
31.19
(13.13%)
268.66 USD
A
ARWR
-1.160
(-4.06%)
27.410 USD
C
CRBP
-0.500
(-0.84%)
59.160 USD
C
CRMD
-0.10000
(-2.19%)
4.47000 USD
D
DRRX
-0.11000
(-6.71%)
1.53000 USD
M
MRTX
0
(0%)
0.000000 USD
S
SGMO
-0.09690
(-12.11%)
0.70340 USD
S
SRPT
1.650
(1.16%)
144.000 USD
V
VKTX
-2.380
(-4.18%)
54.610 USD
الأخبار المقالات

العنوان: Regulus Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.